Status:
COMPLETED
MEDITOXIN® Treatment in Subject With Benign Masseteric Hypertrophy
Lead Sponsor:
Medy-Tox
Conditions:
Masseter Muscle Hypertrophy
Eligibility:
All Genders
20-65 years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy and safety of MEDITOXIN in subjects with benign masseteric hypertrophy compared with placebo
Eligibility Criteria
Inclusion
- subject who aged 20 to less than 65 years
- subject with benign masseteric hypertrophy
Exclusion
- subject not appropriate for participating in this study according to the investigator's opinion
- subject with known an anaphylactic response to BoNT/A and other involved ingredients of Investigational product
Key Trial Info
Start Date :
April 9 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 16 2019
Estimated Enrollment :
180 Patients enrolled
Trial Details
Trial ID
NCT03452345
Start Date
April 9 2018
End Date
April 16 2019
Last Update
July 28 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kangbuk Samsung Hospital
Seoul, South Korea, 03181